Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Journal of the American College of Radiology : JACR|June 1, 2024
ACR Appropriateness Criteria® Hydronephrosis on Prior Imaging-Unknown Cause, Pat Whitworth, Kelsey G Courtney, et al.Annals of Surgical Oncology|April 28, 2017
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)Peter Beitsch, Pat Whitworth, Paul Baron, et al.Annals of Surgical Oncology|April 6, 2021
The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving SurgeryChirag Shah, Troy Bremer, Charles Cox, et al.Annals of Surgical Oncology|April 29, 2020
Legacy Genetic Testing Results for Cancer Susceptibility: How Common are Conflicting Classifications in a Large Variant Dataset from Multiple Practices?Kanhua Yin, Yuxi Liu, Basanta Lamichhane, et al.Annals of Surgical Oncology|July 30, 2016
A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during ExcisionCharles E Cox, Scott Russell, Vanessa Prowler, et al.JCO Precision Oncology|November 4, 2022
Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry CompositionElisha Hughes, Susanne Wagner, Dmitry Pruss, et al.International Journal of Radiation Oncology, Biology, Physics|July 20, 2025
Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence RatesFrank Vicini, Chirag Shah, Karuna Mittal, et al.JNCI Cancer Spectrum|August 12, 2025
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world dataAdam M Brufsky, Kent F Hoskins, Henry J Conter, et al.Annals of Surgical Oncology|April 5, 2022
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast CancerPat Whitworth, Peter D Beitsch, James V Pellicane, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.Pageof 6